Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) was $47.34 for the day, up 0.49% from the previous closing price of $47.11. In other words, the price has increased by $0.49 from its previous closing price. On the day, 0.92 million shares were traded. RARE stock price reached its highest trading level at $47.465 during the session, while it also had its lowest trading level at $45.58.
Ratios:
Our analysis of RARE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.65 and its Current Ratio is at 2.81. In the meantime, Its Debt-to-Equity ratio is 2.63 whereas as Long-Term Debt/Eq ratio is at 2.46.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on June 06, 2024, Upgraded its rating to Buy and sets its target price to $67 from $56 previously.
On April 22, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.Wells Fargo initiated its Overweight rating on December 08, 2023, with a $72 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 10 ’24 when Horn Howard sold 7,465 shares for $52.76 per share. The transaction valued at 393,853 led to the insider holds 92,301 shares of the business.
KAKKIS EMIL D sold 20,000 shares of RARE for $1,117,000 on Sep 03 ’24. The President & CEO now owns 2,223,985 shares after completing the transaction at $55.85 per share. On Sep 03 ’24, another insider, Huizenga Theodore Alan, who serves as the SVP, Chief Accounting Officer of the company, sold 91 shares for $56.19 each. As a result, the insider received 5,113 and left with 41,551 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 4371579392 and an Enterprise Value of 4680304640. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.36 while its Price-to-Book (P/B) ratio in mrq is 12.59. Its current Enterprise Value per Revenue stands at 8.953 whereas that against EBITDA is -9.341.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $60.37, while it has fallen to a 52-week low of $37.02. The 50-Day Moving Average of the stock is -7.93%, while the 200-Day Moving Average is calculated to be -1.68%.
Shares Statistics:
RARE traded an average of 694.74K shares per day over the past three months and 461980 shares per day over the past ten days. A total of 92.24M shares are outstanding, with a floating share count of 83.30M. Insiders hold about 9.79% of the company’s shares, while institutions hold 92.12% stake in the company. Shares short for RARE as of 1731628800 were 3346228 with a Short Ratio of 4.82, compared to 1728950400 on 3164918. Therefore, it implies a Short% of Shares Outstanding of 3346228 and a Short% of Float of 4.16.
